Introduction

The composition of the eukaryotic cytoskeleton consists mainly of three discrete fibrous structures—actin microfilaments, microtubules and intermediate filaments. These structures provide the framework to maintain cell shape and polarity and also contribute to other fundamental cellular functions such as motility, organelle transport and division [1]. These cellular processes are carried out through the actions of multiple molecules, which comprise functional modules [2]. These interactions can be seen in cryoelectron tomography images, in which functional modules appear to be spatially congested while at the same time highly organized [3,4]. It has been suggested that an intact actin cytoskeleton is fundamentally responsible for the functional organization within the cell [5].

In ECs, the cytoskeleton plays an essential role in providing a sturdy intracellular scaffold, which serves to organize vital membrane proteins within the cell. The cytoskeleton also has the ability to respond to extracellular stimuli and undergo reorganization [6]. Additionally, several lines of evidence support the notion that numerous soluble proteins can be associated with the cytoskeleton [5]. These findings boost the role of the cytoskeleton as not only the defining structure of the cell, but also as a key regulator of the intracellular environment [7].

When ECs are quiescent, actin creates a cortical ring providing a link between cell-cell and cell-matrix adhesion complexes and intracellular organelles. The cortical actin ring is necessary to sustain the EC barrier function [8] and its disruption can initiate EC permeability [9]. When ECs are stimulated with inflammatory agonists such as thrombin and histamine, the cortical actin ring is reorganized in such a manner that stress fibers are created, which extend throughout the cell [10].

Understanding how ECs respond to stimuli that mediate cytoskeleton changes is an important topic in organ allograft rejection. Antibodies directed toward HLA class I molecules on the donor endothelium play a major role in antibody-mediated
transplant rejection [11]. Several studies suggest that the signaling events that occur in EC following the binding of HLA class I antibodies contribute to the process of chronic rejection and transplant vasculopathy. Signaling through the HLA class I molecules on the surface of ECs is associated with changes in the actin cytoskeleton. HLA class I ligation on ECs activates the GTP binding protein RhoA [12] and utilizes Rho GTPase and Rho-kinase (ROK) to promote stress fiber formation [13]. In addition, HLA class I ligation activates Src, focal adhesion kinase (FAK), and paxillin [14]. FAK is central regulator of this signaling cascade as it is critical for focal adhesion assembly and stress fiber formation [15]. These signaling cascades represent early events leading to activation of downstream pathways in the endothelium that can be detrimental to graft survival. One such pathway is the proliferation pathway. The mammalian target of rapamycin (mTOR) is an essential regulator of cell proliferation and protein synthesis through the activation of p70 ribosomal S6 kinase (S6K) and eukaryotic initiation factor 4E-binding protein 1 (4E-BP1) [16,17]. Ligation of HLA class I molecules on the surface of ECs promotes proliferation via the mTOR pathway [18]. Understanding how cytoskeleton changes contribute to these signaling cascades will advance our understanding of EC proliferation, migration and permeability, all of which may contribute to the mechanism(s) underlying antibody-mediated transplant rejection.

Here we present the results of a proteomic-based analysis characterizing changes in the cytoskeleton of human aortic ECs following stimulation with thrombin, basic fibroblast growth factor and HLA class I antibodies. The contents of these isolations were further characterized. TPM4, eIF4A1 and DDX3X, were uniquely found in the list of HLA class I-induced cytoskeleton associated proteins was characterized. Three of the candidates, TPM4, eIF4A1 and DDX3X, were further characterized. TPM4 was uniquely found in the cytoskeletal fraction of class I stimulated ECs, but absent in the cytoskeleton of ECs stimulated with thrombin and bFGF. The eIF4A1 protein, a regulator of protein synthesis and cell proliferation, was found in association with the actin cytoskeleton by Western blot and shown a higher degree of colocalization with F-actin and paxillin in HLA class I stimulated cells compared to the other treatment groups. This proteomic discovery approach provides candidate targets, which may link HLA class I-induced cytoskeleton changes to downstream cellular functions such as proliferation.

**Materials and Methods**

**Ethics Statement**

Informed written consent for use of the aortic tissue as an anatomical gift for research was obtained by OneLegacy (a federally-designated organ procurement organization) at the time of organ donation from the next of kin or authorized party. The use of the human aortic tissue for the research described herein was approved by the OneLegacy Biomedical Review Board under the agreement #RS-02-10-2 and UCLA MTA2009-561.

**Antibodies and Chemicals**

Cytochalasin D was purchased from Sigma-Aldrich. Recombinant human bFGF was purchased from R&D Systems. Human α-thrombin was from Enzyme Research Laboratories. The murine monoclonal antibody W6/32 (IgG2a), reactive with a monomorphic epitope on HLA class I antigens, was obtained from the American Type Culture Collection. The mouse IgG used as an isotype control was supplied by Sigma-Aldrich. Recombinant human FGF basic was from R&D Systems. Antibodies used for Western blot were β-actin, eIF4A1, 4E-BP1 obtained from Cell Signaling and vinculin, β-tubulin, and myosin light chain (all three from Santa Cruz) and β1-integrin and paxillin (BD Biosciences) and TPM4 and DDX3X (both from Acris Antibodies). The eIF4A1 antibody used for confocal microscopy was obtained from Santa Cruz. A second eIF4A1 antibody obtained from Abcam was used to confirm the specificity of the immunofluorescent staining pattern. The fluorescent conjugated secondary antibodies, Alexa-fluor 488 goat anti-rabbit, Rhodamine Red TM-X goat anti-mouse and Texas Red-phalloidin were from Invitrogen.

**Cell Culture**

Primary human aortic ECs were isolated from the aortic rings of explanted donor heart tissues, as previously described [19]. ECs were cultured in M199 complete medium composed of sodium pyruvate (1 mM) (Irvin Scientific), penicillin (100 U/ml) and streptomycin (100 µg/ml) (both from Invitrogen), 20% (v/v) FBS (HyClone), heparin (90 µg/ml) (Sigma-Aldrich), and endothelial cell growth supplement (20 µg/ml) (Fisher Scientific). Cells from passages 4–10 were used at 80%–90% confluence.

**F-actin Staining**

ECs grown to 80–90% were starved for 2 h in basal medium containing 0.2% FBS followed by treatment with mAb W6/32 (1 µg/ml) (referred to as HLA class I stimulated), isotype control mouse IgG (1 µg/ml) (referred to as unstimulated), thrombin (1 U/ml) or bFGF (25 ng/ml) for 10 min. Treated ECs were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton X-100. The presence of F-actin was visualized by direct staining with Texas Red-phalloidin. Cells were analyzed with Zeiss Axioplan 2 microscope with the Zeiss FluorArc 100 watt mercury light source. Digital images of fluorescence were obtained with a cooled charge-coupled device camera (SPOT 2, Diagnostic Instruments) and associated software (SPOT 4.5, Diagnostic Instruments).

**Cytoskeleton Isolation**

The method was adapted from a previously published method [7]. Prior to use in experiments, ECs were grown for 16 h in medium containing 0.2% FBS. ECs were treated with mAb W6/32 (1 µg/ml), mouse isotype control IgG (1 µg/ml), thrombin (1 U/ml) or bFGF (25 ng/ml) for 10 min at 37°C, washed once with ice-cold PBS and lysed in buffer containing 20 mM Tris (pH 7.9), 137 mM NaCl, 5 mM EDTA, 1 mM EGTA, 10% glyc erol, 1% Triton X-100, 10 mM NaF, 1 mM PMF, 1 mM Na3VO4, 10 µg/ml aprotinin, and 10 µg/ml leupeptin for 10 min on ice. The samples were sonicated for 30 sec. Tosylactivated Dynal-beads M280 (50 µl/sample) (Invitrogen) were first pre-blocked using a blocking buffer (0.5 M Tris, 1 M glycine). Next the beads were washed once with PBS. The lysate was then added to the beads and the mixture incubated on ice for 15 min with intermittent mixing. The beads were collected by a magnetic particle concentrator (MPC) (Dynal) and washed 2 times with PBS and 2 times with 10 mM Tris-HCl pH 8.

**Western Blot**

Beads containing the cytoskeleton isolation preparations were heated for 5 min at 95°C in SDS sample buffer, electrophoresed on SDS polyacrylamide gels, and transferred to a polyvinylidene difluoride membrane. The membranes were blocked using 5% nonfat dry milk in TBS (pH 7.4) containing 0.1% Tween 20 (TBST) for 20 min at room temperature, and incubated with the appropriate primary antibody overnight at 4°C. The blots were washed with TBST followed by incubation in HRP-conjugated
secondary antibody (Santa Cruz Biotechnology) for 1 h at room temperature. The blots were subsequently washed with TBST and developed with ECL.

In-Solution Tryptic Digestion

Beads containing the cytoskeleton proteins were resuspended in digestion buffer (50 mM ammonium bicarbonate). The sample was first reduced using 100 mM DTT (Sigma-Aldrich). Next, the preparation was alkylated using 100 mM iodoacetamide (Sigma Aldrich). The proteins were then digested overnight using proteomics grade trypsin (Sigma Aldrich) at a concentration of 0.1 µg/µl. Following trypsin digest, the beads were centrifuged at 14,000 x g for 1 min and the supernatant was collected.

Peptide Purification

Magnetic Dynabeads RPC 18 (Invitrogen) were used to bind the cytoskeleton peptides for purification. RPC 18 beads were first washed with binding buffer (0.1% TFA/0.5%ACN). The cytoskeleton peptides were mixed with binding buffer then added to the beads. The beads were washed 4 times with binding buffer and eluted with 60% ACN.

Nano-liquid chromatography with tandem mass spectrometry (nLC-MSMS)

nLC-MS/MS with Collision Induced Dissociation (CID) is performed on a 7 tesla LTQ FT Ultra (Thermo Scientific, Waltham, MA) integrated with an Eksigent nano-LC. A prepacked reverse-phase column (Microtech Scientific C18 with a dimension of 100 µm x 3.5 cm) containing reverse-phase resin (Biobasic C18, 5-µm particle size, 300-A pore size, Microtech Scientific, Fontana, CA) is used for peptide chromatography and subsequent CID analyses. ESI conditions using the nano-spray source (Thermo Fisher) for the LTQ-FT are set as follows: capillary temperature of 250°C, tube lens 110 V and a spray voltage of 2.5 kV. The flow rate for reverse-phase chromatography is 5 µl/min for loading and 300 nl/min for the analytical separation (buffer A: 0.1% formic acid, 1% ACN; buffer B: 0.1% formic acid, 100% ACN). Peptides are resolved by the following gradient: 2-60% buffer B over 40 min, then increased to 80% buffer B over 10 min and then returned to 0% buffer B for equilibration of 10 min. The LTQ-FT is operated in data-dependent mode with a full precursor scan at high-resolution (100000 at m/z 400) and six MSMS experiments at low resolution on the linear trap while the full scan is completed. For CID the intensity threshold was set to 5000, where mass range was 350–2000. Spectra are searched using Mascot software (Matrix Science, UK) in which results with p<0.05 (95% confidence interval) were considered significant and indicating identity. The data was also analyzed through Sequest database search algorithm implemented in Discoverer software (Thermo Fisher, Waltham, MA).

Confocal Microscopy

ECs were grown on 35 mm glass bottom dishes to 80–90% confluence and starved for 2 h in basal medium containing 0.2% FBS followed by treatment with mAb W6/32 (1 µg/ml), isotype control mouse IgG (1 µg/ml), thrombin (1 U/ml) or bFGF (25 ng/ml) for 10 min. Treated ECs were fixed with 4% paraformaldehyde and permeabilized with 0.2% Triton-X-100. Cells were incubated with primary antibody (mouse anti-paxillin or rabbit anti- eIF4A1) in 5% BSA in PBS overnight at 4°C washed and incubated with secondary antibody (Alexafluor 488 goat anti-rabbit for eIF4A1 and Rhodamine RedTM-X goat anti-mouse IgG for paxillin) for 30 min at room temperature. The presence of F-actin was visualized by direct staining with Texas Red-phalloidin. Cell images were captured using a Zeiss LSM 510 confocal microscope at 63× magnification using the Zeiss LSM 5 PASCAL software (Carl Zeiss MicroImaging GmbH, Germany)

Results

HLA class I ligation induces stress fiber formation

A comparison of F-actin reorganization by immunofluorescence revealed that stimulation with HLA class I antibodies (Fig. 1B) or thrombin (Fig. 1C) activated stress fiber formation, while bFGF (Fig. 1D) failed to produce stress fibers. Stimulation of ECs with an antibody to HLA class I showed an 86% increase in the mean fluorescence intensity of F-actin staining (p = 5E-07). Thrombin stimulation also significantly increased the mean fluorescence intensity of F-actin staining by 139% (p = 2E-09), whereas stimulation with bFGF decreased F-actin staining by 11% compared to the unstimulated cells (Fig. 1E). Although both thrombin and HLA class I antibodies triggered actin remodeling, the HLA class I antibody-induced stress fiber response was weaker than that induced by thrombin (Fig. 1C vs 1B). We examined the effects of low and high doses of thrombin and compared it to the signaling pathways elicited by anti-HLA class I antibodies (MZ unpublished data). Stimulation with thrombin at high concentrations (1 U/ml) induced a robust increase in the intracellular Ca²⁺ concentration and promoted stress fiber formation in an ERK-independent manner. In contrast, stimulation of ECs with either HLA class I antibodies or a low dose of thrombin (1 µU/ml) did not promote any detectable change in intracellular Ca²⁺ concentration, but induced myosin light chain (MLC) phosphorylation and stress fiber assembly via MLC kinase (MLCK) and ROK in an ERK1/2-dependent manner. Thus, the pathway activated by the high dose of thrombin is different from the pathway activated by a lower dose of thrombin and HLA class I ligation. Given these observations, we hypothesized that the isolation and proteomic characterization of the cytoskeletal proteins in HLA class I stimulated ECs could lead to a better understanding of the mechanisms underlying HLA class I induced stress fibers.

The EC cytoskeleton can be isolated

Previous studies showed that the cytoskeleton and its associated proteins could be selectively enriched using Dynal beads [7]. The cytoskeleton was isolated from unstimulated ECs and ECs stimulated with an HLA class I antibody, thrombin or bFGF. For the following Western blot experiments, ECs were also treated with a cytochalasin D followed by cytoskeleton isolation. Western blot analysis revealed that when an intact cytoskeleton was isolated from ECs, the cytoskeleton proteins vinculin, β-tubulin, MLC and β-actin were detected, while disruption of the cytoskeleton with cytochalasin D prevented the isolation of these proteins (Figure 2A). Previous studies demonstrated the absence of β1 integrin in the cytoskeleton fraction marks the selective enrichment of the cytoskeleton and its associated proteins [7,20]. When the cytoskeleton was isolated from ECs, the β1 chain of integrin was only detected in the cytoskeleton-depleted fraction and was not found in the cytoskeleton-enriched fraction (Figure 2B).

Identification of cytoskeleton associated proteins

Using in-solution trypsin digestion the isolated cytoskeleton fraction from each treatment group was digested into peptides. To identify the proteins in the cytoskeleton isolation preparations, nLC-MS/MS was performed on the peptides and Mascot searches
were carried out. The list of proteins identified in each treatment group is summarized in Table S1. A total of 128 cytoskeleton-associated proteins were identified in unstimulated ECs, 126 in HLA class I stimulated ECs, 67 in thrombin treated ECs and 88 in bFGF treated ECs. When these proteins were compared between the treatment groups we identified 62 unique proteins in the unstimulated group, 56 in the HLA class I group, 10 in the thrombin group and 20 in the bFGF group.

Classification of the cytoskeleton proteins

The identified proteins were classified using the Gene Ontology (GO) enrichment analysis tool Gene Onology Tree Machine (GOTM) [21]. The results are represented as a directed acyclic graph (DAG) in order to preserve the relationships among the enriched GO categories. For each treatment group, a DAG was produced and certain GO categories were significantly enriched in each data set. Figure 3 is a re-creation of the DAG generated by GOTM for the HLA class I stimulated group. The grey boxes are categories that were not significantly enriched, while the significantly enriched categories found in the HLA class I treated group are shown by the white boxes and include the adjusted p-values [using Benjamini Hochberg] and the number of proteins found in each category. The significantly enriched categories in the HLA class I treated group were compared to the other treatment groups and if the categories in the class I group were also enriched in any of the other treatment groups then these categories were not considered a unique category of HLA class I unique cytoskeleton changes. The categories found to be uniquely enriched by HLA class I stimulation are indicated by the boldfaced boxes (Fig. 3).

To determine which proteins are important for inducing HLA class I cytoskeleton changes, the proteins found under the unique categories of the HLA class I DAG were examined (Fig. 3, boldfaced boxes). Using this list of proteins in the HLA class I group,
each protein was searched in the original list of unstimulated, thrombin and bFGF treated cells (Table S1). If a protein found under the HLA class I unique category was also found in any of the other treatment groups it was not considered a candidate protein. After eliminating the proteins that were also found in the other treatments groups, 12 candidate proteins were identified (Table 1).

Prediction of protein kinases

Among the 12 candidates identified, 11 of the proteins were phosphoproteins with the exception of RCF4 (Table 1). The 11 candidate phosphoprotein sequences and their corresponding phosphorylation sites were submitted to the online-software NetworKIN-2.0, which provides a list of kinase predictions and grants insight into the interaction networks between phosphoproteins and kinase families based on the latest human phosphoproteome [22]. Using the known phosphorylation sites of the 11 candidate phosphoproteins it was determined that 35 kinase families could be responsible for their activation and among these 35 families there were 70 individual kinases (Table 2).

To determine the role these kinases may play in HLA class I cytoskeleton activation the 70 protein kinases were annotated using GOanna [23] and the GO terms were then categorized using CateGOrizer [24]. The top three GO categories represented by the 70 kinases were cell communication (26%), metabolism (14%) and signal transduction (11%) (Fig. 4).

Validation of protein candidates

To confirm the presence of the candidate proteins in the cytoskeleton fraction, we performed Western blot experiments with antibodies to 3 of these candidate proteins, DDX3X, TPM4 and eIF4A1 (Table 1). MLC, a well documented component of the actin cytoskeleton, was found in the cytoskeleton fraction of all treatment groups, but absent in the cytoskeleton fractions following treatment with cytochalasin D (Fig. 5A). Similarly, all 4 treatment groups showed DDX3X in the cytoskeleton fraction, but not when the cytoskeleton was disrupted using cytochalasin D. TPM4 was only found in the cytoskeleton fraction of ECs treated with anti-HLA class I antibodies and its association with the cytoskeleton was abrogated by pretreatment with cytochalasin D (Fig. 5A).

Among the list of candidates, eIF4A1 was selected for further characterization because it functions as a downstream target of mammalian target of rapamycin (mTOR) [25] and we previously reported a role for mTOR in class I-mediated cell proliferation [18]. The cytoskeleton isolation was repeated for each treatment group, and various proteins in the cytoskeleton fraction were compared to the total cell lysate and the depleted fraction of the cytoskeleton by Western blot. As expected, the known cytoskeleton components, β-actin and MLC, were found in the cytoskeleton fraction (Fig. 5B). eIF4A1 was also found in the cytoskeleton fraction of all treatment groups (Fig. 5B). However, eIF4A1 was no longer captured in the cytoskeleton fraction following treatment with cytochalasin D. These data demonstrate that capture of the total cytoskeleton contains eIF4A1 in all 4 of the treatment conditions when examined by Western blot.

We next examined HLA class I-induced eIF4A1 interactions with the cytoskeleton by performing cellular colocalization studies. For this, confocal microscopy was performed to determine the degree of colocalization of eIF4A1 with F-actin and paxillin, both

Figure 2. Validation of the EC cytoskeleton isolation by Western blot. (A) Human aortic ECs were treated for 10 min with either mIgG 1 μg/ml (lane 1), HLA class I Ab 1 μg/ml (lane 2), thrombin 1 U/ml (lane 3), bFGF 25 ng/ml (lane 4) or treated with cytochalasin D 5 μM (lane 5) for 30 min. The cytoskeleton was isolated from the lysates using tosylactived magnet Dynal beads and the fraction was analyzed by Western blot for components of the cytoskeleton. (B) Human aortic ECs were treated for 10 min with either mIgG 1 μg/ml (lanes 1 and 6), HLA class I Ab 1 μg/ml (lanes 2 and 7), thrombin 1 U/ml (lanes 3 and 8), bFGF 25 ng/ml (lanes 4 and 9) or treated with cytochalasin D 5 μM (lanes 5 and 10) for 30 min. The cytoskeleton was isolated using tosylactived magnetic Dynal beads. The cytoskeleton fraction (lanes 6–10) and the depleted fraction after cytoskeleton isolation (lanes 1–5) were immunoblotted to detect the presence of β1-integrin and β-actin as a loading control. The data presented in panels A and B are representative of 5 independent experiments. doi:10.1371/journal.pone.0029472.g002
of which are known regulators of HLA class I cytoskeleton changes [14]. Figure 6A shows the localization of eIF4A1 and F-actin in the ECs. The colocalization image (Fig. 6B) generated by the ImageJ plugin was used to calculate changes in the level of colocalization (Fig. 6C). The eIF4A1 protein aligned with F-actin stress fibers in both the HLA class I and thrombin stimulated ECs. The degree of colocalization was more prominent in ECs treated with HLA class I antibodies compared to thrombin treated ECs, but this difference did not reach statistical significance (p = 0.07). The colocalization intensity of eIF4A1 and F-actin following HLA class I stimulation was statistically significant when compared to the unstimulated (p = 0.006) and bFGF treated groups (p = 0.002). To assess the specificity of the association between eIF4A1 and the actin cytoskeleton, we repeated this experiment using a second antibody recognizing a different epitope on eIF4A1. We observed a similar pattern of immunofluorescence staining and degree of colocalization, confirming the colocalization of eIF4A1 with F-actin stress fibers (Figure S1).

Figure 7A represents the staining pattern and localization of eIF4A1 and paxillin. The colocalization image (Fig. 7B) determined by the ImageJ plugin was used to compare the degree of alignment of these two proteins (Fig. 7C). Similar to the results obtained with F-actin, EC stimulated with HLA class I antibodies and thrombin exhibited a higher degree of colocalization with paxillin than cells treated with bFGF or isotype control IgG. Although the increased alignment of eIF4A1 and paxillin was more prominent after HLA class I ligation compared to thrombin (p = 0.09), the difference was only statistically significant when compared to the mIgG (p = 0.01) and bFGF (p = 0.003) treatment groups. These results indicate increased colocalization of eIF4A1 with F-actin and paxillin following HLA class I stimulation.

Discussion

The actin cytoskeleton is an important regulator of various cellular functions in ECs including proliferation, migration and...
permeability [26]. To gain insights into the molecular processes underlying HLA class I-mediated actin stress fiber remodeling we conducted a proteomic analysis of the cytoskeletal fractions of ECs treated with anti-HLA class I antibodies and contrasted these findings to thrombin and bFGF-induced cytoskeletal remodeling. Here we report a novel method to examine the composition of the EC cytoskeleton and reveal unique cytoskeleton proteomes in ECs depending on the agonist used for stimulation. Using annotation tools, a candidate list was created that revealed 12 potential HLA class I-induced targets that may play a role in understanding EC cytoskeleton changes.

Among the list of candidates, we identified proteins or related proteins involved in cytokinesis dynamics. For example, cortactin is a known actin-binding protein and transduces signaling to the cytoskeleton [27,28]. It also has the ability to cross-link F-actin, which is regulated by Src-kinase mediated activation [29]. Additionally, the actin-related protein 2/3 (Arp2/3) complex is essential in the regulation of actin polymerization and localizes to sites of dynamic actin [30]. To tie these processes together one group reported that cortactin colocalizes with both dynamic actin and the nuclear pore complex protein Nup153. DDX3X was confirmed by Western blot to be associated with the isolated cytoskeleton fraction following HLA class I ligation on the surface of ECs stimulates the formation of actin stress fibers and the activation of Src family kinases [14]. Thus, it is plausible that HLA class I-mediated Src kinase phosphorylation may regulate cortactin binding protein 2 and Arp2/3 complex subunit 3 in the formation of stress fibers following class I ligation.

In the past, we established that HLA class I signaling cascades involve various phosphorylation events and have explored several key proteins responsible for these events [14,32]. The current data add to our understanding of these phosphorylation events as we explored the kinases that have the potential to phosphorylate the candidate proteins. Among the kinase predictions, cyclin-dependent kinase 2 (CDK2) has the potential to phosphorylate 3 of the candidate proteins. CDK2 has already been established as a regulator of HLA class I signal transduction. HLA class I ligation on the surface of ECs leads to the inactivation of retinoblastoma protein (Rb) and this happens through CDK2 [33]. Rb is negative regulator of cell cycle progression [34]. Activation of CDK2 represses the inhibition put forth by Rb and this allows the ECs to pass the G1 checkpoint and proliferate [33]. The current study elucidated several candidate targets of CDK2, which may contribute to a better understanding of the molecular processes involved in HLA class I-mediated signal transduction leading to cell proliferation.

Another kinase family predicted to be involved in the phosphorylation of the candidate proteins is 70-kDa S6 protein kinase (p70S6k) family, where the specific kinase was ribosomal protein S6 kinase 1 (S6RP). HLA class I ligation leads to the phosphorylation of p70S6k and S6RP, which are downstream of mTOR complex 1 [18]. It has yet to be determined which S6RP downstream targets are important in HLA class I signaling. The current findings suggest that S6RP may phosphorylate two of the candidate proteins, ATP-dependent RNA helicase DDX3X and nuclear pore complex protein Nup153. DDX3X was confirmed by Western blot to be associated with the isolated cytoskeleton fraction following HLA class I ligation on ECs. DDX3X interacts with TANK binding kinase 1 to activate the interferon (IFN) promoter. When DDX3X protein levels are reduced using RNAi, type I IFN production is diminished [35]. Cytokine production is associated with allograft rejection [36] and in vitro, cytokines are known to synergize with HLA class I antibodies to enhance signal transduction [37]. Little is known about the regulation of HLA class I induced cytokine production and DDX3X may be a potential target in controlling cytokine induction. Recent findings suggest that Nup153 is crucial for nucleoskeleton and cytoskeleton architecture maintenance and is necessary for cell cycle progression and cell migration. In addition, when Nup 153 is knocked down by RNAi, there is prominent cytoskeleton rearrangement.

Table 1. 12 Candidate Proteins Representing HLA Class I Induced Cytoskeleton Changes.

| Accession | Protein Name                  | Gene Name | GO Categories                      |
|-----------|-------------------------------|-----------|-----------------------------------|
| Q8WZ74    | Cortactin-binding protein 2   | CTTNBP2   | protein polymerization            |
|           |                                |           | cellular protein complex assembly  |
|           |                                |           | macromolecular complex assembly    |
|           |                                |           | protein complex biogenesis         |
| O15145    | Actin-related protein 2/3 complex subunit 3 | ARPC3 | protein polymerization            |
|           |                                |           | cellular protein complex assembly  |
|           |                                |           | macromolecular complex assembly    |
|           |                                |           | protein complex biogenesis         |
| Q99880    | Histone H2B type 1-L          | HIST1H2BL | macromolecular complex assembly    |
| P83731    | 60S ribosomal protein L24     | RPL24     | macromolecular complex assembly    |
| P04114    | Apolipoprotein B-100          | APOB      | macromolecular complex assembly    |
| P11142    | Heat shock cognate 71 kDa protein | HSP48 | hydrolase activity, acting on acid anhydrides|
| O00571    | ATP-dependent RNA helicase DDX3X | DDX3X | hydrolase activity, acting on acid anhydrides|
| P60842    | Eukaryotic initiation factor 4A-I | EIF4A1 | hydrolase activity, acting on acid anhydrides|
| P35249    | Replication factor C subunit 4 | RFC4     | hydrolase activity, acting on acid anhydrides|
| P49790    | Nuclear pore complex protein Nup153 | NUP153 | hydrolase activity, acting on acid anhydrides|
| P60576    | ATP synthase subunit beta, mitochondrial | ATP5B   | hydrolase activity, acting on acid anhydrides|
| P67936    | Tropomyosin alpha-4 chain     | TPM4      | actin cytoskeleton                |

doi:10.1371/journal.pone.0029472.t001
| Kinase Family | Kinases | Candidate Phosphoproteins |
|--------------|---------|---------------------------|
| ACTR2_ACTR2B_TGFbR2 | TGF-beta type II receptor | HSPA8, NUP153 |
| ACTR2 | Activin receptor type II | DDX3X |
| AMPK | AMPK alpha-1 chain | RPL24 |
| ATM_ATR | Serine-protein kinase ATR | HSPA8, DDX3X |
| ATM | Serine-protein kinase ATM | HSPA8, DDX3X |
| AuroraA | Serine/threonine-protein kinase 6 | hist1h2bl |
| AuroraB | Serine/threonine-protein kinase 12 | DDX3X |
| CaMKIIalpha_CaMKIIdelta | CaM-kinase II alpha chain | RPL24 |
| CaMKIIbeta_CaMKIIgamma | CaM-kinase II gamma chain | NUP153 |
| CDK2_CDK3 | Cell division protein kinase 2 | APOB, EIF4A1, NUP153 |
| CDK4_CDK6 | Cell division protein kinase 4 | HSPA8 |
| CK2 | Casein kinase II, alpha chain | CTNBP2, HSPA8, ATP5B, APOB, RPL24, DDX3X, NUP153 |
| CLK | Dual specificity protein kinase CLK1 | DDX3X, hist1h2bl |
| CLK2 | Dual specificity protein kinase CLK2 | DDX3X, hist1h2bl |
| DMPK | Myotonic-protein kinase | RPL24 |
| EGFR | Receptor tyrosine-protein kinase erbB-1, erbB-2, erbB-3, erbB-4 | HSPA8 |
| EphA7_EphA6_EphA4_EphA3_EphA5 | Ephrin type-A receptor 4, 7, 3 | DDX3X, TPM4 |
| FLT3_CSF1R_Kit | Mast/stem cell growth factor receptor | ARPC3, DDX3X |
| GSK3 | Glycogen synthase kinase-3 beta | HSPA8, DDX3X, NUP153 |
| InsR | Insulin-like growth factor 1 receptor | HSPA8, DDX3X, NUP153, TPM4 |
| JNK | Mitogen-activated protein kinase 8 | NUP153 |
| MAP2K6_MAP2K3_MAP2K4_MAP2K7 | Dual specificity mitogen-activated protein kinase 4 | HSPA8, DDX3X |
| MAPK3_MAPK15_MAPK7_NLK | Mitogen-activated protein kinase 3 | NUP153 |
| Met | Hepatocyte growth factor receptor | HSPA8 |
| NEK1_NEK5_NEK3_NEK4_NEK11_NEK2 | Serine/threonine-protein kinase Nek2 | HSPA8, DDX3X, NUP153 |
| p38 | Mitogen-activated protein kinase 14 | NUP153 |
| p70S6K | Ribosomal protein S6 kinase | NUP153 |
| PAKA | Serine/threonine-protein kinase PAK 1 | HSPA8, DDX3X, NUP153 |
| PAKB | Serine/threonine-protein kinase PAK 4 | DDX3X |
that hinders cell migration in human breast carcinoma cells [38]. The integrity of the cytoskeleton is key to HLA class I signaling [14,15] and given the role of Nup153 it seems that this protein would be worth investigating.

TPM4 was identified as a candidate protein in the HLA class I treated group by mass spectrometry and confirmed by Western blot to be present only in the cytoskeleton fraction of HLA class I stimulated ECs. Tropomyosins are among the most abundant cytoskeletal proteins in ECs [39]. By mass spectrometry, tropomyosin-1 was identified as an oxidative-stress-sensitive phosphoprotein in ECs [40]. H2O2 induced the activation of DAP kinase, downstream of ERK. DAP kinase promoted the phosphorylation of tropomyosin-1, which was essential for H2O2 induced formation of actin stress fibers in ECs [41]. HLA class I ligation leads to ERK activation [18] and thus, it would be valuable to determine if TPM4 functions downstream of ERK as regulator of HLA class I induced cytoskeleton remodeling.

The eIF4A1 protein, functions downstream of mTOR complex 1, which has been shown to phosphorylate 4E-BP1 following class I ligation [18]. 4E-BP1 is bound to eIF4E and when 4E-BP1

---

**Table 2. Cont.**

| Kinase Family | Kinases | Candidate Phosphoproteins |
|--------------|---------|--------------------------|
| PAK          | Serine/threonine-protein kinase PAK 7 | DDX3X |
| PDGFR        | Beta platelet-derived growth factor receptor | HSPA8 |
| Alpha platelet-derived growth factor receptor | HSPA8 |
| Pim2         | Serine/threonine-protein kinase Pim-2 | RPL24, DDX3X |
| Pim3_Pim1    | Proto-oncogene serine/threonine-protein kinase Pim-1 | DDX3X |
| PKA          | cAMP-dependent protein kinase, beta-catalytic subunit | NUP153 |
| PKC          | Protein kinase C, delta type | HIST1H2BL, NUP153 |
| PKC          | Protein kinase C, zeta type | HIST1H2BL, NUP153 |
| PKC          | Protein kinase C, iota type | HIST1H2BL, NUP153 |
| PKC          | Protein kinase C, theta type | HIST1H2BL, NUP153 |
| PKC          | Protein kinase C, alpha type | HIST1H2BL, NUP153 |
| PKC          | Protein kinase C, gamma type | HIST1H2BL, NUP153 |
| PKD          | Protein kinase, D1 type | HSPA8 |
| Tec          | Tyrosine-protein kinase ITK/TSK | ARPC3 |
| Tec          | Tyrosine-protein kinase BTK | ARPC3 |
| Tec          | Tyrosine-protein kinase Tec | ARPC3 |
| TLK          | Serine/threonine-protein kinase tousled-like 1 | DDX3X, HIST1H2BL |

doi:10.1371/journal.pone.0029472.t002

---

**Figure 4. GO categories represented by the 70 kinases.** The 70 predicted kinases thought to have the potential to phosphorylate the 11 candidate phosphoproteins were annotated using GOanna and the annotations were categorized using CateGOrizer which mapped the kinases based on EGAD2GO. The GO terms mapped to 47 EGAD2GO ancestor terms and this graph represents the top 17 definitions and the rest are grouped into the “other” category.

doi:10.1371/journal.pone.0029472.g004
Figure 5. DDX3X, TPM4 and eIF4A1 in the EC cytoskeleton fraction. (A) The EC cytoskeleton was isolated for the 4 treatment groups, mIgG 1 µg/ml (lane 1), HLA class I 1 µg/ml (lane 2), thrombin 1 U/ml (lane 3), bFGF 25 ng/ml (lane 4) and ECs that were treated with cytochalasin D (5 µM, 30 min) (lane 5). The total cell lysate and the cytoskeleton fraction were subjected to SDS-PAGE separation followed by Western blot to examine the presence of MLC, DDX3X and TPM4 proteins. (B) The EC cytoskeleton isolation was isolated for the 4 treatment groups, mIgG 1 µg/ml (lane 1), HLA class I 1 µg/ml (lane 2), thrombin 1 U/ml (lane 3) and bFGF 25 ng/ml (lane 4). The total cell lysates, depleted fractions and the cytoskeleton isolated fractions were subjected to SDS-PAGE separation followed by Western blot to examine β-actin, total MLC and eIF4A1 protein levels in different cell fractions. (C) The cytoskeleton isolation was performed on ECs treated with mIgG 1 µg/ml for 10 min (lane 1) or with cytochalasin D (lane 2) 5 µM for 30 min. The total cell lysates, depleted fractions and cytoskeleton isolated fractions were subjected to SDS-PAGE separation followed by Western blot to examine eIF4A1, total MLC and β1-integrin in the cell fractions. The results presented in panel A and B are representative of 5 and 3 independent experiments, respectively. doi:10.1371/journal.pone.0029472.g005

becomes phosphorylated eIF4E is released and recruited to eIF4F, which includes both eIF4A1 and eIF4G. This complex promotes translation and cell proliferation [25]. The link between translational machinery and the cytoskeleton was postulated some time ago [42]. Continued efforts to make this connection showed that when the soluble fraction of a cell lysate was compared to the cytoskeleton fraction, certain initiation factors where enriched in the cytoskeleton and one of those factors was eIF4A1 [43]. It has yet to be determined how the cytoskeleton could regulate and organize translation.

Although eIF4A1 and DDX3X were found by mass spectrometry to be exclusively in the HLA class I treated EC, surprisingly these proteins were found at approximately equal levels in all of the treatment groups following cytoskeleton isolation and Western blotting. The most likely explanation for the detection of eIF4A1 and DDX3X by mass spectrometry only in the class I treated group is the difference in the sensitivity of these assays. In the ECs treated with bFGF or thrombin, other more abundant cytoskeletal proteins may have been present which reduced the relative amount of DDX3X and eIF4A1, precluding their detection by mass spectrometry. Indeed, even when highly sensitive mass spectrometers are used to analyze complex biological samples and bodily fluids, high-abundance proteins obscure the detection of lower-abundance proteins [44].

An alternative explanation for these discrepant findings is that different protein-protein interactions in the treatment groups influence the ability to detect a protein by mass spectrometry. For example, the function of eIF4A1 has little to do with its protein level and more to do with whether or not it is being inhibited [45]. Programmed Cell Death 4 (PDCD4) is a tumor suppressor known to bind eIF4A1, which inhibits translation initiation and proliferation [46]. Detection of eIF4A1 in the cytoskeleton of all treatment groups by Western blot would not be hindered if it is bound to PDCD4, but detection by mass spectrometry could be masked.

We found that treatment with HLA class I antibodies or thrombin stimulated varying degrees of colocalization between eIF4A1 and F-actin and paxillin suggesting that eIF4A1 may interact with specific compartments of the cytoskeleton in a unique manner. Consistent with this concept, recent studies by our laboratory identified two different signaling pathways leading to MLC phosphorylation and stress fiber formation in ECs, depending upon the nature of the stimulus (ME Ziegler, unpublished). Stimulation with thrombin at 1 U/ml induced a robust increase in the intracellular Ca2+ concentration, increased phosphorylation of MLC and promoted stress fiber formation via MLCK and ROK in an ERK-independent manner. In contrast, stimulation of ECs with a low dose of thrombin (1 µU/ml) or HLA class I antibodies did not promote any detectable change in intracellular Ca2+ concentration, but induced MLC phosphorylation and stress fiber assembly via MLCK and ROK in an ERK1/2-dependent manner. HLA class I ligation requires the recruitment of integrin β4 in order to activate proliferation and migration [47]. In carcinoma migration, α6β4 integrin functions via its ability to promote and stabilize F-actin [48]. Additionally, cdk4/6 initiation factors in migrating cells localize with focal adhesions, which contain actin and this up-regulation of localized translation is thought to be a result of integrin engagement [49,50]. These data suggest that the increased colocalization of eIF4A1 with F-actin and paxillin following class I ligation may be in response to the HLA class I molecule partnering with integrin β4 to elicit intracellular signals. Although the colocalization data supports a molecular interaction between eIF4A1 and F-actin and paxillin, additional experiments are required to definitively prove a physical interaction between these proteins. eIF4A1 was suggested to be a potential target for developing new anti-cancer and anti-inflammatory drugs given evidence of cross-talk between translation and the inflammatory response [51]. Our findings suggest that eIF4A1 may also be a potential therapeutic target of HLA class I antibody-mediated rejection.

An important functional consequence of HLA class I ligation on ECs is stimulation of cell proliferation, which we previously reported to occur in subconfluent ECs [15,52]. To gain knowledge on the cytoskeleton changes involved in class I-mediated cell proliferation, we used subconfluent ECs to conduct these experiments. However, the EC density is an important factor that influences cellular responses. Confluent ECs regulate thrombosis, inflammation, vascular cell proliferation and matrix remodeling, whereas subconfluent ECs promote these events [53]. Cell morphology, expression of cell surface molecules and behavior
of the ECs differ in subconfluent versus confluent ECs [54]. Additionally, the EC response to an agonist varies depending on cell density [55,56]. A quiescent EC monolayer is more similar to the in vivo setting in appearance and differentiated properties [57,58]. We have yet to explore the cytoskeletal proteome of a confluent monolayer of ECs in response to HLA class I ligation and postulate that a confluent monolayer may respond differently and utilize distinct signaling pathways.

A key question is how signal transduction is orchestrated through these molecular interactions to stimulate actin cytoskeletal remodeling. Our previous publications and current data are consistent with a model whereby molecular aggregation of HLA class I molecules with antibodies leads to recruitment of integrin β1 and the subsequent activation of intracellular signals that increase Rho-GTP activity, induce phosphorylation of ROK and trigger the assembly and phosphorylation of FAK, Src and paxillin at the focal adhesions to stimulate actin reorganization [13,14,15,47]. The new candidate proteins identified in this study may further contribute to this model. Candidates such as TPM4, eIF4A1, DDX3X, cortactin binding protein 2 and Arp2/3 may be recruited to the focal adhesions to regulate cell proliferation and survival. Similar signaling cascades have been described following antibody cross-linking of ICAM-1 on ECs. ICAM-1 ligation induced cytoskeleton changes, which included increased intracellular calcium, protein kinase C activation, phosphorylation of cortactin and other actin-binding proteins by Src, activation of RhoA GTPase, and subsequent rearrangements of the actin [59,60,61,62,63].

In conclusion, these studies provide new information that can be applied to the exploration of known pathways. Given that phosphoprotein signal transduction is essential to HLA class I EC activation, not only are the proteins relevant, but also their corresponding kinases. Thus, validation of these proteins and examination of their activation state will be important in future studies.
Overall, these studies may reveal more specific targets in understanding the mechanisms of HLA class I induced antibody-mediated rejection. Additionally, these methods can be applied to other cell types and agonists as an effort to understand the role of cytoskeleton changes in many pathways.

**Supporting Information**

**Figure S1 Validation of eIF4A1 localization.** The localization of eIF4A1 and paxillin in the EC was determined by confocal microscopy. The scale bar is equal to 10 μm. Data is representative of 4 independent experiments. eIF4A1 and paxillin colocalization was determined by the ImageJ plugin Colocalization Finder. Mander’s Overlap coefficients were 0.977 (mIgG), 0.929 (HLA class I), 0.933 (thrombin) and 0.888 (bFGF). The data represents 4 independent experiments. (C) Intensities of the colocalization of 3 images per group were determined for each independent experiment (Avg ± SD: mIgG (14.3 ± 4.3), HLA class I (30.2 ± 4.1), thrombin (19.1 ± 7.8) and bFGF (11.7 ± 3.0). The colocalization intensity of eIF4A1 and paxillin in the HLA class I treated group was significantly increased compared to the unstimulated and bFGF groups; mIgG (p = 0.01), thrombin (p = 0.09) and bFGF (p = 0.003) as determined by student t-test. doi:10.1371/journal.pone.0029472.g007

**Table S1 Identity of Proteins in the Cytoskeleton Preparations of Each Treatment Group.** To identify the proteins in the cytoskeleton isolation preparations, nLC-MS/MS was performed on the peptides and Mascot searches were carried out. A total of 128 cytoskeleton-associated proteins were identified.

---

Figure 7. Colocalization of eIF4A1 and Paxillin. (A) The localization of eIF4A1 and paxillin in the EC was determined by confocal microscopy. Cell were treated and prepared for staining and microscopy. The scale bar is equal to 10 μm. Data is representative of 4 independent experiments. (B) eIF4A1 and paxillin colocalization was determined by the ImageJ plugin Colocalization Finder. Mander’s Overlap coefficients were 0.977 (mIgG), 0.929 (HLA class I), 0.933 (thrombin) and 0.888 (bFGF). The data represents 4 independent experiments. (C) Intensities of the colocalization of 3 images per group were determined for each independent experiment (Avg ± SD: mIgG (14.3 ± 4.3), HLA class I (30.2 ± 4.1), thrombin (19.1 ± 7.8) and bFGF (11.7 ± 3.0). The colocalization intensity of eIF4A1 and paxillin in the HLA class I treated group was significantly increased compared to the unstimulated and bFGF groups; mIgG (p = 0.01), thrombin (p = 0.09) and bFGF (p = 0.003) as determined by student t-test. doi:10.1371/journal.pone.0029472.g007

---

Characterization of Endothelial Cell Cytoskeleton
in unstimulated ECs, 126 in HLA class I stimulated ECs, 67 in thrombin treated ECs and 85 in bFGF treated ECs. (DOC)

Author Contributions
Conceived and designed the experiments: MEZ JPW EFR. Performed the experiments: MEZ PS Y-JH. Analyzed the data: MEZ PS. Contributed reagents/materials/analysis tools: MEZ PS Y-JH JPW EFR. Wrote the paper: MEZ EFR.

References
1. Pollard TD, Borisy GG (2003) Cellular mobility driven by assembly and disassembly of actin filaments. Cell 112: 453–465.
2. Kurnar J, Medalia O, Lianoullis AA, Baumeister W (2004) New insights into the structural organization of rukovskite and prokaryotic cytoskeletons using cryo-electron tomography. Exp Cell Res 301: 38–42.
3. Medalia O, Weber I, Frangakis AS, Nicastro D, Gersch G, et al. (2002) Macromolecular architecture in eukaryotic cells visualized by cryo-electron tomography. Science 298: 1209–1213.
4. Steven AC, Arbi U (2003) The next ice age: cryo-electron tomography of intact cells. Trends Cell Biol 13: 107–110.
5. Sere PA (2000) Macromolecular interactions: tracing the roots. Trends Biochem Sci 25: 150–153.
6. Praus N, Stevens T (2009) The actin cytoskeleton in endothelial cell phenotypes. Microvasc Res 77: 53–63.
7. Meng X, Wilkins JA (2005) Compositional characterization of the cytoskeleton of NK-like cells. J Proteome Res 4: 2081–2087.
8. Lee JS, Goddis CK, AP (2005) Microtubules regulate aortic endothelial cell actin microfilament reorganization in intact and repairing monolayers. Histochem Histochem 20: 455–463.
9. Shasby DM, Shasby SS, Sullivan JM, Peach MJ (1982) Role of endothelial cell cytoskeleton in control of endothelial permeability. Circ Res 51: 657–661.
10. Dukde SM, Garcia JC (2001) Cytoskeletal regulation of pulmonary vascular permeability. J Appl Physiol 91: 1407–1500.
11. Colvin RB, Smith RN (2005) Antibody-mediated organ-allograft rejection. Nat Rev Immunol 5: 907–917.
12. Gougel S, Lebeuf F, Boudguy G, Soulillou JP, Charreau B (2004) RhoA activation mediates phosphatidylinositol 3-kinase-dependent proliferation of human vascular endothelial cells: an alloimmune mechanism of chronic alloimmune nephropathy. J Am Soc Nephrol 15: 2429–2439.
13. Lepin EJ, Jin YP, Barwe SP, Rozengurt E, Reed EF (2004) HLA class I signal transduction is dependent on Rho GTpase and ROK. Biochem Biophys Res Commun 323: 212–217.
14. Jin YP, Singh RP, Du ZY, Rajasekaran AK, Rozengurt E, et al. (2002) Ligation of HLA class I molecules on endothelial cells induces phosphorylation of Sr+, paxillin, and focal adhesion kinase in an activin-dependent manner. J Immunol 168: 5415–5423.
15. Jin YP, Korin Y, Zhang X, Jindra PT, Rozengurt E, et al. (2007) RNA interference elucidates the role of focal adhesion kinase in HLA class I-mediated focal adhesion complex formation and proliferation in human endothelial cells. J Immunol 178: 7911–7922.
16. Kim DH, Sarbasov DD, Ali SM, King JG, Latex RR, et al. (2002) mTOR interacts with raptor to form a nutrient-sensitive complex that signals to the cell growth machinery. Cell 110: 163–173.
17. Nojima H, Tokunaga C, Eguchi S, Oshiro N, Hidaya S, et al. (2003) The mammalian target of rapamycin (mTOR) partner, raptor, binds the mTOR substrates p70 S6 kinase and 4E-BP1 through their TOR signaling (TOS) motif. J Biol Chem 278: 15461–15464.
18. Jindra PT, Jin YP, Rozengurt E, Reed EF (2008) HLA class I antibody-mediated endothelial cell proliferation via the mTOR pathway. J Immunol 180: 2357–2366.
19. Zhang B, Schmoyer D, Kirov S, Snoddy J (2004) GOTree Machine (GOTM): a web-based platform for interpreting sets of interesting genes using Gene Ontology hierarchies. BMC Bioinformatics 5: 16.
20. Hynes RO (2002) Integrins: bidirectional, allosteric signaling machines. Cell 110: 673–687.
21. Jin YP, Korin Y, Wang X, Zhang X, Jindra PT, et al. (2008) Increased transcription of IL-8 in endothelial cells is differentially regulated by HLA class I antibody-mediated activation of the PI3K/Akt signaling pathway and induction of Bcl-2 and Bcl-xl expression in endothelial cells. Hum Immunol 65: 291–307.
22. Nath N, Bhan H, Reed EF, Chellappan SP (1999) HLA class I-mediated induction of cell proliferation involves cyclin E-mediated inactivation of Rb function and induction of E2F activity. J Immunol 162: 5351–5358.
23. Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81: 325–330.
24. Soural D, Burchrattmer T, Westerman S, Goncalves A, Bauch A, et al. (2008) The DEAD-box helicase DDX3X is a critical component of the TANK-binding kinase 1-dependent innate immune response. Embo J 27: 2135–2146.
25. Hancock WW, Whitley WD, Bailey WM, 3rd, Tilney NL (1992) Cells, cytoskeletons, adhesion molecules, and humoral responses in a rat model of chronic renal allograft rejection. Transplant Proc 24: 2315–2316.
26. Bhan H, Reed EF (1999) Alloantibody-mediated class I signal transduction in endothelial cells and smooth muscle cells: enhancement by H2d-7e gamma and TNF-alpha. J Immunol 163: 1010–1018.
27. Zhou L, Pante N (2010) The neucleoprin Nup153 maintains nuclear envelope architecture and is required for cell migration in tumor cells. FEBS Lett 584: 1026–1031.
28. Patton WF, Yoon MU, Alexander JS, Chang-Welch N, Hechman HR, et al. (1990) Expression of simple epithelial cytokeratins in bovine pulmonary microvascular endothelial cells. J Cell Physiol 143: 140–149.
29. Houle F, Rousseau S, Morrice N, Luc M, Songnain S, et al. (2003) Extracellular signal-regulated kinase mediates phosphorylation of tropomyosin-1 to promote cytoketin remodeling in response to oxidative stress: impact on membrane blebbing. Mol Biol Cell 14: 1418–1432.
30. Houle F, Pouirer A, Dumarques J, Huot J (2007) DAP kinase mediates the phosphorylation of tropomyosin-1 downstream of the ERK pathway, which regulates the formation of stress fibers in response to oxidative stress. J Cell Sci 120: 3666–3677.
31. Cervera M, Dreyfuss G, Feman S (1981) Messenger RNA is translated when associated with the cytoketin framework in normal and VSV-infected HeLa cells. Cell 23: 113–120.
32. Howe JG, Hershey JW (1984) Translational initiation factor and ribosome association with the cytoketin framework fraction from HeLa cells. Cell 37: 85–93.
33. Bandhakavi S, Markowski TW, Xie H, Griffith TJ (2011) Three-dimensional peptide fractionation for highly sensitive nanoscale LC-based shotgun proteomic analysis of complex protein mixtures. Methods Mol Biol 790: 47–56.
34. Botley A, Phillips NM, Webb TE, Willis AE, Spriggs KA (2010) eIF4A inhibition allows translational regulation of mRNAs encoding proteins involved in Alzheimer’s disease. PLoS One 5.
35. Suzuki C, Garces RG, Edmonds KA, Hiller S, Hyberts SG, et al. (2008) PDCD4 inhibits translation initiation by binding to eIF4A using both its MA3 domains. J Biol Chem 283: 15461–15464.
36. Hancock WW, Whitley WD, Baldwin WM, 3rd, Tilney NL (1992) Cells, cytoskeleton remodeling in response to oxidative stress: impact on membrane blebbing. Mol Biol Cell 14: 1418–1432.
37. Hobara T, Yamagishi T, Takahashi H, Kashiwagi A, Oono Y (2007) Flow cytometric analysis of complex protein mixtures. Methods Mol Biol 790: 47–56.
38. Noble W, Zhang J, Van Roey J, Morgan G, Krzysztof M, et al. (2010) Compartmentalisation and compartmentalisation of complex protein mixtures. Methods Mol Biol 790: 47–56.
39. Michalak K, Korin Y, Zhang X, Jindra PT, et al. (2008) Characterization of Endothelial Cell Cytoskeleton.
52. Jindra PT, Zhang X, Mulder A, Claas F, Veale J, et al. (2006) Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 82: S33–35.
53. D’Amore PA (1992) Mechanisms of endothelial growth control. Am J Respir Cell Mol Biol 6: 1–8.
54. Vlodavsky I, Gospodarowicz D (1979) Structural and functional alterations in the surface of vascular endothelial cells associated with the formation of a confluent cell monolayer and with the withdrawal of fibroblast growth factor. J Supramol Struct 12: 75–114.
55. Brunner PM, Heier PC, Mihaly-Bison J, Prieglter U, Binder BR, et al. (2011) Density enhanced phosphatase-1 down-regulates urokinase receptor surface expression in confluent endothelial cells. Blood 117: 4154–4161.
56. Vinals F, Pouyssegur J (1999) Confluence of vascular endothelial cells induces cell cycle exit by inhibiting p12/p44 mitogen-activated protein kinase activity. Mol Cell Biol 19: 2763–2772.
57. Barber KA (1995) Changes in surface topography in endothelial monolayers with time at confluence: influence on subcellular shear stress distribution due to flow. Biochem Cell Biol 73: 501–505.
58. Vlodavsky I, Johnson LK, Gospodarowicz D (1979) Appearance in confluent vascular endothelial cell monolayers of a specific cell surface protein (CSP-60) not detected in actively growing endothelial cells or in cell types growing in multiple layers. Proc Natl Acad Sci U S A 76: 2306–2310.
59. Durieu-Trautmann O, Chaverot N, Cazaubon S, Strosberg AD, Couraud PO (1994) Intercellular adhesion molecule 1 activation induces tyrosine phosphorylation of the cytoskeleton-associated protein cortactin in brain microvascular endothelial cells. J Biol Chem 269: 12536–12540.
60. Etienne S, Adamson P, Greenwood J, Strosberg AD, Cazaubon S, et al. (1998) ICAM-1 signaling pathways associated with Rho activation in microvascular brain endothelial cells. J Immunol 161: 5753–5761.
61. Adamson P, Etienne S, Couraud PO, Calder V, Greenwood J (1999) Lymphocyte migration through brain endothelial cell monolayers involves signaling through endothelial ICAM-1 via a rho-dependent pathway. J Immunol 162: 2964–2973.
62. Etienne-Manneville S, Manneville JB, Adamson P, Wilbourn B, Greenwood J, et al. (2000) ICAM-1-coupled cytoskeletal rearrangements and transendothelial lymphocyte migration involve intracellular calcium signaling in brain endothelial cell lines. J Immunol 165: 3375–3383.
63. Couty JP, Rampon C, Levque M, Laran-Chich MP, Bourdoulous S, et al. (2007) PECAM-1 engagement counteracts ICAM-1-induced signaling in brain vascular endothelial cells. J Neurochem 103: 793–801.